Bypass Operation by Single-Style Esophageal Plasty Using Small Intestines for Patients with End-Stage Esophageal Cancer which was Impossible to be Cured Radically
Abstract
The purpose of this study is to figure out the possibility of the bypass operation in esophageal cancer which is impossible to be cured radically and its effect on the survival rate and quality of life of the patients. In recent years, the incidence of the esophageal cancer has been increasing, thus there are many problems occurred in keeping the QOL. Especially gastrostomosis is being done in order to improve dysphagia in esophageal cancer patients who missed the optimal operation time but the patients are suffering themselves due to the psychological burden about the gastrostoma and mental factors to miss the time and even some of them are requiring the operation in those situations. We studied on three patients diagnosed as the esophageal cancer (impossible to be cured radically) from March, 2021 to March, 2022. All the patients were males and the average age was 53.3. All of them had end-stage esophageal cancer and among them, two were T3 N2 M0 and the other one was T3 N2 M1 . We concluded the radical cure by the esophagotomy was impossible and performed bypass operation (single-style esophageal plasty using small intestine). On discharge, we evaluated the satisfactory of the patients about the operation, and postoperative survival duration, and the quality of life by WHOQOL-100. After operation, the patients’ QoL has been improved and the survival duration has been elongated from six months in the past to 12.7 months. Esophageal bypass operation by single-style esophageal plasty is an effective treatment to keep the patients’ QoL, who has esophageal cancer impossible to be incised and increase the survival duration.

Copyright (c) 2024 Gi-Yong Ri, Yong-Jin Ryu, Hyon-Jong Kim, Un Sung, Hyo-Il Song, Ryong-Un Kim, Sung-Ho Kim, Il-Su Jo, Chol-Ho Hyon, Sung-Rim Pak, Jung-Hyok Jo

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.